Financial Data and Key Metrics Changes - Full year 2022 sales of Biktarvy grew 20% year-over-year to $10.4 billion, exceeding $10 billion for the first time [8] - Total product sales for 2022 were $27 billion, flat compared to 2021, with growth in the base business offset by a decline in Veklury sales [14][39] - Non-GAAP diluted earnings per share was $1.67 in Q4 2022 compared to $0.69 in Q4 2021, impacted by a $0.25 charge from the termination of the Trodelvy collaboration [42] Business Line Data and Key Metrics Changes - HIV sales for Q4 2022 were $4.8 billion, a 5% year-over-year increase, driven by higher demand and favorable pricing dynamics [14] - Oncology sales, including Trodelvy, reached $680 million for the full year, up 79% year-over-year [23] - Cell therapy sales in Q4 were $490 million, up 75% year-over-year, driven by the uptake of Yescarta [25] Market Data and Key Metrics Changes - The U.S. PrEP market grew 18% year-over-year, with Descovy sales for Q4 at $537 million, up 13% year-over-year [15] - The overall HIV treatment market in the U.S. grew 1.5% year-over-year in Q4, with Europe seeing over 2% growth [15] - Veklury sales for 2022 totaled $3.9 billion, with Q4 sales at $1 billion, indicating a sustainable role in treating COVID-19 [22] Company Strategy and Development Direction - The company is focused on expanding its HIV portfolio and oncology business, with significant clinical progress expected in 2023 [7][9] - Gilead aims to enhance its market position with the recent approval of Sunlenca for multi-drug resistant HIV, targeting a small but significant patient population [20] - The company plans to continue investing in R&D, with expectations of 23 active Phase III trials by the end of 2023 [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the base business's growth trajectory, despite the expected decline in Veklury sales [50] - The company anticipates total product sales in 2023 to range from $26 billion to $26.5 billion, with base business growth projected at 4% to 6% [44] - Management highlighted the importance of maintaining a strong pipeline and adapting to market dynamics, particularly in the COVID-19 treatment landscape [68] Other Important Information - Non-GAAP product gross margin was 86.8%, up more than 16 percentage points from the previous year, primarily due to a legal settlement charge in 2021 [40] - The company returned over $5 billion to shareholders in 2022, including a 2.7% increase in quarterly cash dividends [47][48] Q&A Session Summary Question: Expectations for earnings growth in the next few years - Management indicated that while the base business is performing well, the impact of Veklury's decline complicates earnings projections, but they expect growth to accelerate in the long run as new products are introduced [50][51] Question: Expected dynamics for lenacapavir following approval - Management noted that lenacapavir targets a specific patient population, and while it's early days, they are optimistic about its potential and the response from physicians [54][55] Question: Differentiation of Trodelvy against competitors - Management emphasized their established market presence and the absence of significant safety issues in their development program, which they believe will support their competitive position [59] Question: Study design for Trodelvy in HR-positive, HER2-negative breast cancer - Management stated that they are still finalizing the study design and will share more details as they progress [62] Question: Confidence in the Fc-silent construct for TIGIT - Management expressed confidence based on clinical data from the ARC-7 trial, which demonstrated benefits of their approach compared to competitors [66]

Q4 & FY22 Financial Results February 2, 2023 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilea ...

Gilead in 2023 and Beyond J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 9 January 2023 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those re ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ:GILD) - **Event**: J.P. Morgan Annual Healthcare Conference - **Date**: January 9, 2023 - **Participants**: - Daniel O'Day - Chairman and CEO - Johanna Mercier - Chief Commercial Officer - Merdad Parsey - Chief Medical Officer - Andrew Dickinson - CFO - Chris Schott - JPMorgan Key Points Company Transformation and Strategy - Gilead has successfully transformed its business over the past three years, focusing on creating a diverse and sustainable portfolio while maintaining its legacy in virology [4][5][6] - The company aims to maximize near-term revenue growth, particularly in HIV and oncology, with a focus on long-acting therapies and expanding oncology programs [8][9][10] HIV Business - Gilead's HIV business is expected to see a positive compound annual growth rate (CAGR) through 2030, driven by the success of Biktarvy and new long-acting therapies [29][30] - Biktarvy holds a 45% market share in the U.S. and continues to grow, with expectations for further growth in 2023 [34] - The long-acting HIV therapy Sunlenca is anticipated to transform HIV prevention, with ongoing trials for both treatment and prevention [14][15] Oncology Portfolio - Gilead's oncology business is now at a $2 billion annual run rate, with strong momentum in cell therapy and promising results from Trodelvy in breast cancer [10][11][17] - Trodelvy is positioned as a preferred agent in second-line metastatic triple-negative breast cancer, with ongoing trials to expand its use in earlier lines of therapy [42][44] - The company is exploring various cancer types with magrolimab and has 14 late-stage trials ongoing across its oncology portfolio [22][23][17] COVID-19 Response - Gilead's antiviral drug Veklury has been used in over 12 million patients globally and continues to be a standard of care for COVID-19 [12] - The company is developing a novel oral COVID medicine, with trials expected to start in the U.S. for non-hospitalized patients [13] M&A and Capital Allocation Strategy - Gilead plans to focus on smaller tuck-in acquisitions rather than large deals, reflecting confidence in its existing portfolio [26][62] - The company repurchased $1.4 billion in shares in 2022, indicating a commitment to returning value to shareholders while investing in its pipeline [26][66] Financial Outlook - Gilead expects significant growth in both top-line and bottom-line performance over the next decade, leveraging its existing infrastructure [68] - The company will provide guidance for 2023 and key clinical milestones in the upcoming year-end results presentation [70] Additional Insights - The company emphasizes the importance of health equity, particularly in developing countries, as it continues to innovate in HIV prevention and treatment [15] - Gilead's leadership in cell therapy is highlighted by its partnerships and ongoing studies, which are expected to expand its market reach [24][25] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting Gilead's commitment to innovation and growth in the biopharmaceutical sector.

Gilead Sciences, Inc. (NASDAQ:GILD) NASDAQ 47th Investor Conference December 7, 2022 8:00 AM ET Company Participants Dan O'Day - Chairman and CEO Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead with us. Just a reminder, personal analyst holding disclosures are available on morganst ...

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler Healthcare Conference November 30, 2022 11:30 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Do Kim - Piper Sandler Do Kim All right. Good morning. And thank you, everyone for joining us for our next company presentation. My name is Do Kim. I am one of the Senior Biotech Analysts here at Piper. And we have with us Gilead, and it's my pleasure to welcome CMO, Merdad Parsey. Merdad, thank you for being here. Merda ...

Gilead Sciences, Inc. (NASDAQ:GILD) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 1:00 PM ET Company Participants Andrew Dickinson - Executive Vice President & Chief Financial Officer William Grossman - Senior Vice President of Oncology Clinical Research Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Umer Raffat Excellent. Thank you guys for joining us. We have tons to review today. Thank you Andy and Bill for joining us. And it' ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - CFO Christi Shaw - CEO, Kite Conference Call Participants Chris Schott - JPM Salveen Richter - Goldman Sachs Brian Abrahams - RBC Michael Yee - Jefferies Brian Skorney - Baird Matthew Harrison - Morgan Stanley Tyler Van Buren - Cowen Umer Ra ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird 2022 Global Healthcare Conference September 14, 2022 9:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney Good morning, everyone. Thank you for joining us our next fireside chat. I'm really pleased to have with me the Chief Commercial Officer of Gilead Sciences, Johanna Mercier. Gilead is a name I'm sure everyone is familiar with. It's one of the bellwethers of the sector, a long- ...